Skip to main content

Table 1 Comparison between the group without and with TMP-SMX as PJP prophylaxis

From: The impact of trimethoprim-sulfamethoxazole as Pneumocystis jiroveci pneumonia prophylaxis on the occurrence of asymptomatic bacteriuria and urinary tract infections among renal allograft recipients: a retrospective before-after study

 

Total

No TMP-SMX

TMP-SMX

P value

 

N = 343 (100 %)

N = 131 (38.2 %)

N = 212 (61.8 %)

 

Variables

    

 Age recipient

52 (40–61)

52 (40–59)

52 (39–61)

0.420

 BMI recipient

25.2 +/−4.5

24.7 +/− 4.2

25.5 +/−4.6

0.128

 Female gender

152 (44.3)

65 (49.6)

87 (41.0)

0.120

 Diabetes Mellitus (a)

94 (27.4)

25 (19.1)

69 (32.5)

0.007

 Age donor

50 (40–57)

49 (39–57)

51 (41–57)

0.232

 Allograft from deceased donor

215 (62.7)

83 (63.4)

132 (62.3)

0.839

 Delayed graft function

109 (31.8)

42 (32.1)

67 (31.6)

0.930

 Acute rejection

80 (23.3)

31 (23.7)

49 (23.1)

0.925

 Indwelling urological catheter (b)

53 (15.5)

10 (7.6)

43 (20.3)

0.002

 First transplantation

294 (85.7)

113 (86.3)

181 (85.4)

0.821

 CMV disease

26 (7.6)

13 (9.9)

13 (6.1)

0.197

Maintenance therapy

   

<0.001

 Tacrolimus-MMF-steroids

205 (59.8)

49 (37.4)

156 (73.2)

 

 MMF-cyclosporine-steroids

38 (11.1)

28 (21.4)

10 (4.7)

 

 MA-cyclosporine-steroids

100 (29.2)

54 (41.2)

46 (21.7)

 

Induction therapy

    

 Basiliximab

216 (63.0)

82 (62.6)

134 (63.2)

0.909

Primary renal disease

    

 Hypertension

88 (25.7)

23 (17.6)

65 (30.7)

 

 Cystic renal disease

49 (14.3)

18 (13.7)

31 (14.6)

 

 IgA nephropathy

28 (8.2)

15 (11.5)

13 (6.1)

 

 Diabetes

20 (5.8)

7 (5.3)

13 (6.1)

 

 Focal segmental glomerulosclerosis

27 (7.9)

11 (8.4)

16 (7.5)

 

 Reflux and anatomical abnormalities

25 (7.3)

11 (8.4)

14 (6.6)

 

 Glomerulonephritis

26 (7.6)

10 (7.6)

16 (7.5)

 

 Unknown origin

27 (7.9)

12 (9.2)

15 (7.1)

 

 Others

53 (15.5)

24 (18.3)

29 (13.7)

 

Bacteriuria outcomes:

    

 No bacteriuria

211 (61.5)

94 (71.7)

117 (55.2)

0.002

 Bacteriuria

132 (38.5)

37 (28.2)

95 (44.8)

 

Subtype of bacteriuria

    

- only ASB

63 (18.4)

17 (13.0)

46 (21.7)

 

- cystitis

26 (7.6)

5 (3.8)

21 (9.9)

 

- AGPN

43 (12.5)

15 (11.5)

28 (13.2)

 
  1. Continuous variables are depicted as mean with +/− standard deviation or as median with (25–75 %) interquartile range. Nominal variables are depicted as the total number analysed with its percentage (%). AGPN allograft pyelonephritis, ASB asymptomatic bacteriuria, CI confidence interval, CMV cytomegalovirus, MA mycophenolic acid, MMF mycophenolate mofetil, TMP-SMX trimethoprim-sulfamethoxazole
  2. a: The variable “diabetes mellitus” includes type 1, type 2 diabetes and new onset of diabetes after transplantation (NODAT), irrespective of whether it was the primary disease which led to renal failure. b: The variable “Indwelling urological catheter” represents Foley catheter, nephrostomy catheter and intermittent self-catheterisation
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us